Home - Products - Angiogenesis - ALK - 5-phenylthieno[2,3-d]pyrimidin-4-amine

5-phenylthieno[2,3-d]pyrimidin-4-amine

CAS No. 195193-10-3

5-phenylthieno[2,3-d]pyrimidin-4-amine( —— )

Catalog No. M28408 CAS No. 195193-10-3

5-phenylthieno[2,3-d]pyrimidin-4-amine is a chemical compound.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 55 In Stock
2MG 36 In Stock
5MG 55 In Stock
10MG 83 In Stock
25MG 141 In Stock
50MG 207 In Stock
100MG 312 In Stock
200MG 445 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    5-phenylthieno[2,3-d]pyrimidin-4-amine
  • Note
    Research use only, not for human use.
  • Brief Description
    5-phenylthieno[2,3-d]pyrimidin-4-amine is a chemical compound.
  • Description
    5-phenylthieno[2,3-d]pyrimidin-4-amine is a chemical compound.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    ALK
  • Recptor
    RARγ
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    195193-10-3
  • Formula Weight
    227.285
  • Molecular Formula
    C12H9N3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Nc1ncnc2scc(-c3ccccc3)c12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.M I Dawson, et al. Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: a potential role for trans-RA-induced ZBP-89 in ODC inhibition. Int J Cancer. 2001 Jan 1;91(1):8-21.
molnova catalog
related products
  • AZD3463

    AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.

  • LDN212854

    LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors.

  • LDK378 dihydrochlori...

    Ceritinib dihydrochloride is a selective, orally bioavailable and ATP-competitive inhibitor of ALK tyrosine kinase(IC50 of 200 pM), and also inhibits IGF-1R, InsR, and STK22D (IC50 values of 8, 7, and 23 nM, respectively).